Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma. This drug was developed by Kyowa Hakko Kogyo Co. , Ltd.

PropertyValue
dbpedia-owl:abstract
  • Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma. This drug was developed by Kyowa Hakko Kogyo Co. , Ltd.
  • L'ecromeximab è un anticorpo monoclonale di tipo chimerico sviluppato per il trattamento del melanoma maligno. Questo farmaco è stato sviluppato dalla Kyowa Hakko Kogyo Co. , Ltd. Il farmaco agisce sull'antigene GD3 ganglioside.
dbpedia-owl:atcPrefix
  • none
dbpedia-owl:casNumber
  • 292819-64-8
dbpprop:atcPrefix
  • none
dbpprop:casNumber
  • 292819 (xsd:integer)
dbpprop:mabType
  • mab
dbpprop:molecularWeight
  • 145255 (xsd:integer)
dbpprop:source
  • xi/o
dbpprop:target
  • GD3 ganglioside
dbpprop:type
  • mab
dbpprop:unii
  • M76FX2JZRM
dbpprop:verifiedfields
  • changed
dbpprop:verifiedrevid
  • 400278939 (xsd:integer)
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma. This drug was developed by Kyowa Hakko Kogyo Co. , Ltd.
  • L'ecromeximab è un anticorpo monoclonale di tipo chimerico sviluppato per il trattamento del melanoma maligno. Questo farmaco è stato sviluppato dalla Kyowa Hakko Kogyo Co. , Ltd. Il farmaco agisce sull'antigene GD3 ganglioside.
rdfs:label
  • Ecromeximab
  • Ecromeximab
owl:sameAs
foaf:page
is owl:sameAs of
is foaf:primaryTopic of